Author:
Chao Nelson J.,Choi Taewoong
Publisher
Springer International Publishing
Reference86 articles.
1. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB (1991) Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 146(10):3523–3527
2. Altmeyer A, Dumont FJ (1993) Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. Cytokine 5(2):133–143
3. Antin JH, Ferrara JL (1992) Cytokine dysregulation and acute graft-versus-host disease. Blood 80(12): 2964–2968
4. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB (2012) Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood 119(25):6145–6154
5. Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH (2008) Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 26(35):5767–5774